Pre-clinical studies of amphethinile, a new anti-mitotic agent
Author Information
Author(s): A.T. McGown, C. Ewen, D.B. Smith, B.W. Fox
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital and Holt Radium Institute
Hypothesis
Amphethinile may have a different mechanism of action compared to vinca alkaloids and could be effective against drug-resistant cancer cells.
Conclusion
Amphethinile shows no cross-resistance with daunorubicin-resistant cells, indicating its potential as an effective treatment for resistant cancers.
Supporting Evidence
- Amphethinile does not show cross-resistance with daunorubicin-resistant cells.
- The drug accumulates differently in resistant and parental cell lines.
- Amphethinile has a beta half-life of approximately 100 minutes in mice.
- The area under the curve (AUC) for amphethinile at the LD10 level was 313 µg l-1 h-1.
Takeaway
Researchers are studying a new cancer drug called amphethinile, which works differently than some existing drugs and might help patients whose cancer doesn't respond to those drugs.
Methodology
The study involved in vitro tests on murine leukemia cells and pharmacokinetic studies in male mice.
Limitations
The study was conducted in vitro and in animal models, which may not fully represent human responses.
Participant Demographics
Male mice were used for pharmacokinetic studies.
Want to read the original?
Access the complete publication on the publisher's website